201 related articles for article (PubMed ID: 25685858)
21. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
22. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Lee FC; Merchant SH
Am J Hematol; 2003 May; 73(1):48-53. PubMed ID: 12701121
[TBL] [Abstract][Full Text] [Related]
23. Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
Prescrire Int; 2016 Mar; 25(169):61-4. PubMed ID: 27152394
[TBL] [Abstract][Full Text] [Related]
24. Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report.
Al Otaibi T; Al Sagheir A; Ludwin D; Meyer R
Transplant Proc; 2007 May; 39(4):1276-7. PubMed ID: 17524952
[TBL] [Abstract][Full Text] [Related]
25. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
[TBL] [Abstract][Full Text] [Related]
26. [Castleman's disease. Discussion related to case report].
Dănăilă C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2000; 104(3):133-41. PubMed ID: 12089914
[TBL] [Abstract][Full Text] [Related]
27. Castleman's disease of the leptomeninges--immunohistochemical findings in 2 cases.
Ropponen KM; Kankkunen JP; Ronkainen A; Vihavainen M; Alafuzoff I
Clin Neuropathol; 2002; 21(6):278-83. PubMed ID: 12489677
[TBL] [Abstract][Full Text] [Related]
28. The use of monoclonal antibodies to treat Castleman's disease.
Robey RC; Mletzko S; Colley C; Balachandran K; Bower M
Immunotherapy; 2014; 6(2):211-9. PubMed ID: 24491093
[TBL] [Abstract][Full Text] [Related]
29. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
30. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous multicentric Castleman's disease mimicking IgG4-related disease.
Takeuchi M; Sato Y; Takata K; Kobayashi K; Ohno K; Iwaki N; Orita Y; Yoshino T
Pathol Res Pract; 2012 Dec; 208(12):746-9. PubMed ID: 23102767
[TBL] [Abstract][Full Text] [Related]
32. [Multicentric Castleman's disease (MCD): recent knowledge of its pathogenesis].
Higashibara M; Horie R; Yoneyama A; Mori S
Rinsho Ketsueki; 1992 Nov; 33(11):1649-60. PubMed ID: 1469779
[No Abstract] [Full Text] [Related]
33. Multicentric Castleman's disease & HIV infection.
Cotter A; Lambert J; O'Gorman P
Ir Med J; 2009 Oct; 102(9):294-5. PubMed ID: 19902650
[TBL] [Abstract][Full Text] [Related]
34. Castleman's disease. A case report.
Arslan D; Oztürk F; Patiroğlu T; Küçükaydin M; Gündüz Z
Turk J Pediatr; 1996; 38(3):361-6. PubMed ID: 8827907
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.
Hsu SM; Xie SS; Hsu PL; Waldron JA
Am J Pathol; 1992 Jul; 141(1):129-38. PubMed ID: 1632458
[TBL] [Abstract][Full Text] [Related]
36. [Evolvement in pathogen factor and pathogenesis of Castleman's disease].
Zhang Y; Li GD; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):812-5. PubMed ID: 16545195
[No Abstract] [Full Text] [Related]
37. Multicentric Castleman's disease in a child with prominent thymic involvement: a case report and brief review of the literature.
O'Reilly PE; Joshi VV; Holbrook CT; Weisenburger DD
Mod Pathol; 1993 Nov; 6(6):776-80. PubMed ID: 8302822
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
39. Rare presentation of unicentric Castleman's disease in the parotid gland.
Reece B; Ord R; Papadimitriou J
J Oral Maxillofac Surg; 2012 Sep; 70(9):2114-7. PubMed ID: 22305675
[TBL] [Abstract][Full Text] [Related]
40. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
